Episode Title: Can You Out-Run Your Cocktail? Exercise, Alcohol, and the Science of Damage Control

Can exercise protect you from the damage alcohol does to your body? Drs. Vikas and Nisha Patel break down the latest peer-reviewed data — including the 2025 HUNT study that found fit drinkers outlive sedentary abstainers — and give you the practical playbook for drinking smarter.

Full Description:

Alcohol is a Group 1 carcinogen. It wrecks your sleep, damages your liver, and the old "red wine is good for your heart" story was built on flawed science. So where does that leave those of us who enjoy a glass of wine at dinner or a cocktail on vacation?

In this episode, Drs. Vikas and Nisha Patel dig into one of the most-requested topics from listeners: can exercise actually offset the health consequences of drinking? They walk through the most important recent research — the 2025 Norwegian HUNT study, the British Journal of Sports Medicine pooled analysis, the UK Biobank data, and a major 2025 Journal of Hepatology paper on liver-specific protection — and translate the findings into clear, practical guidance.

Spoiler: exercise doesn't erase alcohol's damage. But the protective effect is real, measurable, and bigger than most people realize. Fitness turns out to be one of the single most powerful modifiers of alcohol-related risk — especially for women, who face disproportionate harm from alcohol but also derive disproportionate benefit from staying active.

The Patels also get personal, sharing their own evolving relationship with alcohol, why they're not prohibitionists, and why the longevity crowd that never eats out and lives by their sleep score might be missing the point.

In this episode:

• What alcohol actually does to your body (cancer, sleep, liver, heart, brain)
• Why the "red wine protects your heart" story fell apart
• The 2025 HUNT study — fit drinkers vs. sedentary abstainers
• How much exercise you need for the protective effect to kick in
• Why women face higher risk — and get bigger benefit from fitness
• The evolutionary mismatch lens on alcohol and movement
• A 7-point practical playbook for drinking smarter

Timestamps:(00:00) Cold open — and why we're covering this(01:30) What alcohol actually does to your body(03:00) Cancer risk — the conversation nobody has at cocktail hour(04:30) Sleep disruption and the REM rebound effect(06:00) Liver disease and why women are more vulnerable(07:30) The red wine myth, explained(10:00) The million-dollar question — can exercise protect you?(11:00) The 2025 HUNT study breakdown(16:00) Important caveats and study limitations(19:00) British Journal of Sports Medicine pooled analysis(21:00) UK Biobank data on heavy drinkers(23:00) Liver-specific protection — the Journal of Hepatology findings(26:00) Alcohol use disorder and exercise — the Mass General Brigham study(28:00) The evolutionary mismatch angle(34:00) Seven practical takeaways(42:00) The 30-second elevator pitch(44:00) Outro

Connect with us:Website: mdlongevitylab.comSubstack: mdlongevitylab.substack.comInstagram / Threads / TikTok / Bluesky: @MDLongevityLabYouTube: MD Longevity Lab

If this episode was useful, share it with someone who needs to hear it and leave us a review. It genuinely helps more people find the show.

This episode is for educational purposes and is not medical advice. Talk to your physician about decisions regarding alcohol use and exercise, especially if you have underlying health conditions.

The real conversation about GLP-1 medications doesn't end with the prescription. Part 2 is where we get into the uncomfortable truths — the data on muscle loss, the biology of weight regain, the patient safety crisis hiding in the compounding pharmacy space — and more importantly, the complete five-pillar protocol for using these drugs with a long-game mentality. If you're on these medications, considering them, or prescribing them, this episode is required listening.

Part 1 drops alongside this one — start there if you haven't.

In this episode

• Why 39% of weight lost on semaglutide may be lean mass — and what that means for your longevity trajectory
• The muscle-longevity math: how GLP-1-driven sarcopenia can silently trade one risk for another
• Protein targets that actually matter: why the RDA is useless and what 1.6–2.4g/kg actually looks like on a plate
• The leucine threshold — why hitting 25–30g per meal is the trigger for muscle protein synthesis
• Resistance training as non-negotiable: the 2023 data showing body recomposition is achievable on these drugs
• The five-pillar MD Longevity Lab protocol: DEXA, protein architecture, resistance training, metabolic biomarkers, and the full clinical picture
• STEP 4 trial: two-thirds of lost weight regained within one year of stopping — and why that's biology, not failure
• The homeostatic counter-response: ghrelin, leptin, metabolic rate suppression, and why stopping without a foundation is dangerous
• Perimenopause intersection: two simultaneous catabolic forces and why nobody is connecting the dots for women

📝 Go deeper every week: mdlongevitylab.substack.com🌐 mdlongevitylab.com — virtual and in-person consultations available📸 @mdlongevitylab🎧 Subscribe, leave a 5-star review, and send this to someone whose provider handed them a GLP-1 prescription in a three-minute visit and called it care.

📝 Free Substack: mdlongevitylab.substack.com🌐 mdlongevitylab.com📸 @mdlongevitylab🎧 Subscribe, leave a 5-star review, and share this episode with one person who needs to hear it.GLP-1 medications are genuinely revolutionary — and genuinely misunderstood. The real conversation isn't hype or panic. In Part 1, we cover the evolutionary biology behind why these drugs work so powerfully, the full drug landscape from semaglutide to retatrutide, how to actually use the new oral pill formats correctly, and the systemic benefits that go far beyond the number on the scale. Part 2 drops alongside this one — don't skip it.

In this episode

Why our hunger biology was never built for the modern food environment — and what that means for obesity treatment

Semaglutide, tirzepatide, and retatrutide — the generation-by-generation breakdown, trial data, and side effect profile

Oral meds: why the 30-minute fasting window is pharmacologically non-negotiable

SELECT trial: 20% reduction in heart attacks and strokes — in patients without diabetes

Kidney protection, liver healing, sleep apnea, the Alzheimer's signal, and addiction medicine — what the evidence actually shows

"Food noise" isn't a metaphor — it's visible on brain MRI, and these drugs quiet it measurably.